Digital Therapeutics
Software that works like medicine. These companies are creating clinically validated digital tools that treat and manage diseases just like traditional pharmaceuticals, but with the scalability of technology. Professional investors see enormous potential in this rapidly evolving healthcare frontier.
Your Basket's Financial Footprint
This basket's total market capitalisation and its concentration among the largest constituents.
- Large cap concentration suggests lower volatility and broader market performance, likely offering more stability than small cap baskets.
- Treat as a core portfolio holding for steady exposure, not a short-term speculative trade.
- Expect modest, gradual appreciation over time; avoid expecting explosive short-term gains.
DRIO: $51.25M
TDOC: $1.53B
HIMS: $11.16B
- Other
About This Group of Stocks
Our Expert Thinking
Digital therapeutics represents the next evolution in healthcare, where FDA-cleared software serves as medicine itself. These companies create evidence-based interventions delivered directly to patients via apps and platforms, transforming treatment for chronic diseases, mental health conditions, and more.
What You Need to Know
This portfolio spans the digital health ecosystem, from specialized software developers to telehealth platforms and supportive technologies. A key catalyst is growing regulatory acceptance and new reimbursement pathways, validating both the clinical effectiveness and commercial potential of these innovations.
Why These Stocks
We've selected companies whose primary business involves creating software-based medical interventions, ensuring direct exposure to this innovative field. Many are seeing increasing insurance coverage decisions, which is critical for widespread adoption and long-term revenue growth.
Why You'll Want to Watch These Stocks
Software is Becoming Medicine
These companies are creating FDA-cleared apps that actually treat diseases—not just track symptoms. It's an entirely new category of medicine with massive growth potential.
Insurance Companies are Paying
A major catalyst is happening right now: insurers are increasingly covering these digital treatments, unlocking billions in potential revenue that wasn't accessible before.
Early Stage with Big Backers
Major pharmaceutical companies and healthcare systems are partnering with these innovators, signaling their belief in the technology's transformative potential.
Get the full story on this Basket. Read our detailed article on its risks and potential.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Antiviral M&A Wave: Biotech Opportunities in 2025
Merck's $9.2 billion acquisition of Cidara Therapeutics strengthens its antiviral pipeline as a key patent nears expiry. This major deal signals a growing trend of pharmaceutical giants buying smaller biotechs, creating potential opportunities among companies with promising infectious disease therapies.
Streaming Power Dynamics Explained | Content Wars
The resolution of the content dispute between Disney and Google's YouTube TV highlights the critical interdependence of content creators and distributors. This dynamic creates an investment opportunity in companies that are central to the streaming ecosystem, from content production to platform delivery.
Jeep Hybrid Recall Overview: Market Shift Analysis
Stellantis is recalling nearly 113,000 Jeep plug-in hybrids because of a serious engine defect, creating potential investment opportunities. This theme focuses on competing automakers and aftermarket parts suppliers that may benefit from a shift in consumer confidence and repair needs.